MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer

Timo Gemoll; Sarah Strohkamp; Katharina Schillo; Christoph Thorns; Jens K. Habermann

doi:10.18632/oncotarget.6103

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer

Timo Gemoll _, Sarah Strohkamp, Katharina Schillo, Christoph Thorns and Jens K. Habermann

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:43869-43880. https://doi.org/10.18632/oncotarget.6103

Metrics: PDF 1685 views | HTML 2801 views | ?

Abstract

Timo Gemoll1, Sarah Strohkamp1, Katharina Schillo1, Christoph Thorns2, Jens K. Habermann1

1Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

2Department of Pathology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

Correspondence to:

Timo Gemoll, e-mail: [email protected]

Jens K. Habermann, e-mail: [email protected]

Keywords: mass spectrometry, genomic instability, aneuploidy, Tβ-4, prognosis

Received: June 16, 2015 Accepted: October 11, 2015 Published: November 05, 2015

ABSTRACT

DNA aneuploidy has been identified as a prognostic factor for epithelial malignancies. Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) is a powerful tool for direct analysis of multiple proteins in tissue sections while maintaining the cellular and molecular integrity. We compared diploid and aneuploid colon cancer tissues against normal mucosa of the colon by means of IMS.

DNA image cytometry determined the ploidy status of tissue samples that were subsequently subjected to MALDI-IMS. After obtaining protein profiles through direct analysis of tissue sections, a discovery and independent validation set were used to predict ploidy status by applying proteomic classification algorithms [Supervised Neural Network (SNN) and Receiver Operating Characteristic (ROC)]. Five peaks (m/z 2,395 and 4,977 for diploid vs. aneuploid comparison as well as m/z 3,376, 6,663, and 8,581 for normal mucosa vs. carcinoma comparison) were significant in both SNN and ROC analysis. Among these, m/z 4,977 was identified as thymosin beta 4 (Tβ-4). Tβ-4 was subsequently validated in clinical samples using a tissue microarray to predict overall survival in colon cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6103

Publication Alerts

Post-Publication Promotion

Research Papers:

MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer

Abstract